Information Provided By:
Fly News Breaks for December 18, 2019
Dec 18, 2019 | 06:29 EDT
Citi analyst Yigal Nochomovitz raised his price target for Dicerna Pharmaceuticals to $39 from $25 after adding hepatitis B virus to his model given the company's recent partnership with a "prominent pharma player." The analyst believes Dicerna's multiple pharma collaborations support the strength of its platform. Nochomovitz keeps a Buy rating on the shares.
News For DRNA From the Last 2 Days
There are no results for your query DRNA